H.J. Lenz

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

Thierry André, Sara Lonardi, Ka Yeung Mark Wong et al. · Annals of Oncology · 2022 · 253 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

Alexander Pohl, Anthony B. El-Khoueiry, Dongyun Yang et al. · The Pharmacogenomics Journal · 2012 · 44 citations

Medicine, Oncology, Pharmacology +15

Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress.

D. Banerjee, H.J. Lenz, Barbara Schnieders et al. · PubMed · 1995 · 43 citations

Life Sciences, Cell Biology, Molecular Biology +10

Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity.

Jingfang Ju, Debabrata Banerjee, H.J. Lenz et al. · PubMed · 1998 · 35 citations

Medicine, Cancer Biology, Oncology +13

Cyclooxygenase-2 inhibitors in colorectal cancer

J STOEHLMACHER, H.J. Lenz · Seminars in Oncology · 2003 · 31 citations

Medicine, Oncology, Pharmacology +14